Neumora Therapeutics (NASDAQ:NMRA) Receives Buy Rating from Guggenheim

Guggenheim reissued their buy rating on shares of Neumora Therapeutics (NASDAQ:NMRA) in a research report sent to investors on Tuesday,Benzinga reports. They currently have a $14.00 price target on the stock.

NMRA has been the topic of a number of other reports. Royal Bank Of Canada raised Neumora Therapeutics from a “sector perform” rating to an “outperform” rating and raised their target price for the stock from $4.00 to $7.00 in a report on Monday, December 1st. Mizuho set a $6.00 price target on Neumora Therapeutics in a research report on Monday, January 5th. Needham & Company LLC reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Neumora Therapeutics in a research note on Tuesday. William Blair raised Neumora Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday, February 17th. Finally, Leerink Partners assumed coverage on Neumora Therapeutics in a research note on Monday, January 12th. They set an “outperform” rating and a $8.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, Neumora Therapeutics currently has a consensus rating of “Hold” and an average target price of $6.71.

Neumora Therapeutics Stock Up 1.0%

Shares of NMRA stock opened at $1.95 on Tuesday. The company has a current ratio of 6.85, a quick ratio of 6.85 and a debt-to-equity ratio of 0.15. Neumora Therapeutics has a 12 month low of $0.61 and a 12 month high of $3.65. The stock has a market cap of $325.83 million, a P/E ratio of -1.34 and a beta of 2.49. The company has a 50 day simple moving average of $2.74 and a two-hundred day simple moving average of $2.32.

Neumora Therapeutics (NASDAQ:NMRA) last issued its quarterly earnings results on Monday, March 30th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.01). On average, research analysts expect that Neumora Therapeutics will post -1.61 earnings per share for the current year.

Insider Activity

In other news, insider Paul L. Berns sold 9,819 shares of the business’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $3.51, for a total value of $34,464.69. Following the transaction, the insider owned 7,395,185 shares of the company’s stock, valued at approximately $25,957,099.35. The trade was a 0.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold a total of 23,387 shares of company stock worth $82,647 in the last quarter. Company insiders own 26.80% of the company’s stock.

Hedge Funds Weigh In On Neumora Therapeutics

Several institutional investors have recently bought and sold shares of NMRA. Hsbc Holdings PLC bought a new stake in Neumora Therapeutics in the 4th quarter valued at $27,000. Henson Edgewater Management LLC bought a new position in shares of Neumora Therapeutics during the 4th quarter valued at about $292,000. Virtu Financial LLC boosted its holdings in shares of Neumora Therapeutics by 465.7% during the 4th quarter. Virtu Financial LLC now owns 97,408 shares of the company’s stock valued at $174,000 after purchasing an additional 80,189 shares during the last quarter. Invesco Ltd. grew its position in shares of Neumora Therapeutics by 23.8% during the fourth quarter. Invesco Ltd. now owns 227,594 shares of the company’s stock valued at $407,000 after purchasing an additional 43,795 shares in the last quarter. Finally, XTX Topco Ltd purchased a new position in shares of Neumora Therapeutics during the fourth quarter valued at about $204,000. 47.65% of the stock is owned by hedge funds and other institutional investors.

Neumora Therapeutics News Roundup

Here are the key news stories impacting Neumora Therapeutics this week:

• Positive Sentiment: Major firms reaffirmed buy ratings with large price targets—Guggenheim set a $14 target (very large upside) which boosts investor optimism about long‑term value. Guggenheim Reaffirms Buy, $14 PT
• Positive Sentiment: Needham also reaffirmed a buy rating and set an $8 price target, reinforcing analyst backing for NMRA’s pipeline recovery potential. Needham Reaffirms Buy, $8 PT
• Positive Sentiment: Company press release and earnings-call highlights emphasize a strong balance sheet and positive early NMRA‑511 data (claimed effect comparable to marketed agents in a prespecified population), which supports upside if later trials confirm signals. Q4 Results & NMRA-511 Data Release
• Neutral Sentiment: Unusually large options buying (roughly 2,812 calls vs. a daily average ~687) and elevated share volume indicate speculative/levered interest that can amplify moves in either direction.
• Negative Sentiment: The company disclosed a Nasdaq delisting risk that could impair liquidity, shareholder value and future capital access—this raises a material tail‑risk for investors. Nasdaq Delisting Risk Disclosure
• Negative Sentiment: Analyst downgrades and caution followed the KOASTAL‑1 failure (navacaprant) in MDD—this clinical setback and the uncertainty around upcoming KOASTAL‑2/3 readouts weigh on near‑term sentiment. SeekAlpha: Downgrade After Navacaprant Setback
• Negative Sentiment: Q4 EPS missed consensus by $0.01 (reported -$0.35 vs. -$0.34), a small miss but relevant given the company is not yet profitable; adds short‑term pressure on valuation. Earnings Release / Transcript

About Neumora Therapeutics

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.